Evidence map›Paper›PMID 30358441›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2019

Kininogen deficiency or depletion reduces enhanced pause independent of pulmonary inflammation in a house dust mite-induced murine asthma model.

Jack Yang, Cornelis van 't Veer, Joris J T H Roelofs, Jeroen W J van Heijst, Alex F de Vos, Keith R McCrae, Alexey S Revenko, Jeff Crosby, Tom van der Poll

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Adjuvant Effect ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jack YangCenter of Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.ORCID 0000-0002-5548-7771
Cornelis van 't VeerCenter of Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Joris J T H RoelofsDepartment of Pathology, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Jeroen W J van HeijstDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Alex F de VosCenter of Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Keith R McCraeDepartments of Hematology-Oncology and Cellular and Molecular Medicine, Cleveland Clinic , Cleveland, Ohio.
Alexey S RevenkoDrug Discovery and Corporate Development, Ionis Pharmaceuticals, Incorporated, Carlsbad, California.
Jeff CrosbyDrug Discovery and Corporate Development, Ionis Pharmaceuticals, Incorporated, Carlsbad, California.
Tom van der PollCenter of Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
Amsterdam UMC Location University of Amsterdam · NLIonis Pharmaceuticals (United States) · USCleveland Clinic · US

Funding

ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGENR01CA083134 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MCCRAE, KEITH R. · 2000 to 2004
$2.0M
NCI NIH HHS R01 CA083134
6 · The paper itself

Abstract

High-molecular-weight kininogen is an important substrate of the kallikrein-kinin system. Activation of this system has been associated with aggravation of hallmark features in asthma. We aimed to determine the role of kininogen in enhanced pause (Penh) measurements and lung inflammation in a house dust mite (HDM)-induced murine asthma model. Normal wild-type mice and mice with a genetic deficiency of kininogen were subjected to repeated HDM exposure (sensitization on days 0, 1, and 2; challenge on days 14, 15, 18, and 19) via the airways to induce allergic lung inflammation. Alternatively, kininogen was depleted after HDM sensitization by twice-weekly injections of a specific antisense oligonucleotide (kininogen ASO) starting at day 3. In kininogen-deficient mice HDM induced in Penh was completely prevented. Remarkably, kininogen deficiency did not modify HDM-induced eosinophil/neutrophil influx, T helper 2 responses, mucus production, or lung pathology. kininogen ASO treatment started after HDM sensitization reduced plasma kininogen levels by 75% and reproduced the phenotype of kininogen deficiency: kininogen ASO administration prevented the HDM-induced increase in Penh without influencing leukocyte influx, Th2 responses, mucus production, or lung pathology. This study suggests that kininogen could contribute to HDM-induced rise in Penh independently of allergic lung inflammation. Further research is warranted to confirm these data using invasive measurements of airway responsiveness.

Indexed as

AnimalsAsthmaDisease Models, AnimalInflammationKininogensLungMiceMice, Inbred BALB CMice, KnockoutPyroglyphidaeTh2 CellsKininogensairway hyperresponsivenessallergic inflammationasthmahouse dust mitekallikrein-kinin system

Identifiers

PMID30358441
PMCPMC6859420
OpenAlexW2898247861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.